Inhibition of cell contractility using inhibitors of JAK or FAK, ruxolitinib, and VS-4718, respectively, or Rho-kinase (with AT13148) significantly reduces ECM deposition and tumor invasion in PDAC mouse models (Jiang et al., 2016, Laklai et al., 2016). This evidence concerns the gene PTK2 and neoplasm.